Buy Incyte (INCY) Ahead of ASCO Abstract Release - Jefferies
Tweet Send to a Friend
Jefferies analyst Thomas Wei reiterated a Buy rating and $80 price target on Incyte (NASDAQ: INCY) saying they expect the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


